Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies DOI Creative Commons
Yonatan Moges Mesfin, Joseph E. Blais, Kelemu Tilahun Kibret

et al.

Journal of Antimicrobial Chemotherapy, Journal Year: 2024, Volume and Issue: 79(9), P. 2119 - 2131

Published: May 31, 2024

To determine the effectiveness of nirmatrelvir/ritonavir and molnupiravir among vaccinated unvaccinated non-hospitalized adults with COVID-19.

Language: Английский

Long COVID: a clinical update DOI
Trisha Greenhalgh, Manoj Sivan,

Alice Perlowski

et al.

The Lancet, Journal Year: 2024, Volume and Issue: 404(10453), P. 707 - 724

Published: July 31, 2024

Language: Английский

Citations

78

Prevalence of persistent SARS-CoV-2 in a large community surveillance study DOI Creative Commons
Mahan Ghafari, Matthew Hall, Tanya Golubchik

et al.

Nature, Journal Year: 2024, Volume and Issue: 626(8001), P. 1094 - 1101

Published: Feb. 21, 2024

Persistent SARS-CoV-2 infections may act as viral reservoirs that could seed future outbreaks

Language: Английский

Citations

66

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial DOI Creative Commons
William HK Schilling, Podjanee Jittamala, James A Watson

et al.

The Lancet Infectious Diseases, Journal Year: 2023, Volume and Issue: 24(1), P. 36 - 45

Published: Sept. 28, 2023

Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19 antiviral treatments, but their activities in patients have not been compared directly. The aim of this ongoing platform trial is to compare different treatments using rate viral clearance as measure effect.

Language: Английский

Citations

57

Evolution of the SARS-CoV-2 Mutational Spectrum DOI Creative Commons
Jesse D. Bloom, Annabel C. Beichman, Richard A. Neher

et al.

Molecular Biology and Evolution, Journal Year: 2023, Volume and Issue: 40(4)

Published: April 1, 2023

Abstract SARS-CoV-2 evolves rapidly in part because of its high mutation rate. Here, we examine whether this mutational process itself has changed during viral evolution. To do this, quantify the relative rates different types single-nucleotide mutations at 4-fold degenerate sites genome across millions human sequences. We find clear shifts several The most striking trend is a roughly 2-fold decrease rate G→T Omicron versus early clades, as was recently noted by Ruis et al. (2022. Mutational spectra distinguish replication niches. bioRxiv, doi:10.1101/2022.09.27.509649). There also C→T Delta, and other subtle changes spectrum along phylogeny. speculate that these could arise from affect replication, packaging, antagonization host innate-immune factors, although environmental factors play role. Interestingly, more similar than earlier clades to shaped long-term evolution sarbecoviruses. Overall, our work shows dynamic variable suggests may be trending toward animal

Language: Английский

Citations

51

The One Health Concept DOI Creative Commons
S. Pitt,

Alan Gunn

British Journal of Biomedical Science, Journal Year: 2024, Volume and Issue: 81

Published: Feb. 15, 2024

The concept of One Health has been developed as the appreciation that human health is intricately connected to those other animals and environment they inhabit. In recent years, COVID-19 pandemic noticeable effects climate change have encouraged national international cooperation apply strategies address key issues welfare. United Nations (UN) Sustainable Development Goals established targets for wellbeing, clean water sanitation, action, well sustainability in marine terrestrial ecosystems. Quadripartite comprises World Organization (WHO), Animal (WOAH—formerly OIE), Food Agriculture (FAO) Environment Programme (UNEP). There are six areas focus which Laboratory services, Control zoonotic diseases, Neglected tropical Antimicrobial resistance, safety Environmental health. This article discusses by considering examples infectious diseases environmental under each headings. Biomedical Scientists, Clinical Scientists their colleagues working diagnostic research laboratories a role play applying approach healthcare 21st Century.

Language: Английский

Citations

33

The Emergence and Evolution of SARS-CoV-2 DOI
Edward C. Holmes

Annual Review of Virology, Journal Year: 2024, Volume and Issue: 11(1), P. 21 - 42

Published: April 18, 2024

The origin of SARS-CoV-2 has evoked heated debate and strong accusations, yet seemingly little resolution. I review the scientific evidence on its subsequent spread through human population. available data clearly point to a natural zoonotic emergence within, or closely linked to, Huanan Seafood Wholesale Market in Wuhan. There is no direct linking laboratory work conducted at Wuhan Institute Virology. global was characterized by gradual adaptation humans, with dual increases transmissibility virulence until Omicron variant. Of note been frequent transmission from humans other animals, marking it as strongly host generalist virus. Unless lessons are learned, inevitable that more events leading epidemics pandemics will plague populations.

Language: Английский

Citations

31

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients DOI Creative Commons
Joseph F. Standing, Laura Buggiotti, José Afonso Guerra‐Assunção

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: Feb. 23, 2024

Abstract Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been elucidated in at-risk populations. Non-hospitalised participants within 5 days SARS-CoV-2 symptoms randomised to receive (n = 253) or Usual Care 324) were recruited study viral dynamics on whole genome sequence from 1437 genomes. Molnupiravir accelerates load decline, but virus is detectable by Day most cases. At 14 (9 post-treatment), associated with significantly higher persistence lower anti-SARS-CoV-2 spike titres compared Care. Serial sequencing reveals increased mutagenesis treatment. Persistence RNA at group transition mutations following treatment cessation. viability similar both groups post-molnupiravir treated samples cultured up 9 post cessation The current 5-day course too short. Longer courses should be tested reduce risk potentially transmissible molnupiravir-mutated variants being generated. Trial registration: ISRCTN30448031

Language: Английский

Citations

21

Learning from Protein Engineering by Deconvolution of Multi‐Mutational Variants DOI Creative Commons
Frank Hollmann,

Joaquin Sanchis,

Manfred T. Reetz

et al.

Angewandte Chemie International Edition, Journal Year: 2024, Volume and Issue: 63(36)

Published: June 17, 2024

Abstract This review analyzes a development in biochemistry, enzymology and biotechnology that originally came as surprise. Following the establishment of directed evolution stereoselective enzymes organic chemistry, concept partial or complete deconvolution selective multi‐mutational variants was introduced. Early experiments led to finding mutations can interact cooperatively antagonistically with one another, not just additively. During past decade, this phenomenon shown be general. In some studies, molecular dynamics (MD) quantum mechanics/molecular mechanics (QM/MM) computations were performed order shed light on origin non‐additivity at all stages an evolutionary upward climb. Data used construct unique multi‐dimensional rugged fitness pathway landscapes, which provide mechanistic insights different from traditional landscapes. Along related line, biochemists have long tested result introducing two point enzyme for reasons, followed by comparison respective double mutant so‐called cycles, showed only additive effects, but more recently also uncovered cooperative antagonistic non‐additive effects. We conclude suggestions future work, call unified overall picture epistasis.

Language: Английский

Citations

17

Clinical course and management of COVID-19 in the era of widespread population immunity DOI
Eric A. Meyerowitz, Jake Scott, Aaron Richterman

et al.

Nature Reviews Microbiology, Journal Year: 2023, Volume and Issue: 22(2), P. 75 - 88

Published: Dec. 19, 2023

Language: Английский

Citations

35

Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections DOI Creative Commons
Mohammed Nooruzzaman, Katherine Johnson, Ruchi Rani

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: Sept. 18, 2024

Language: Английский

Citations

13